Abstract 1600P
Background
Lenvatinib and pembrolizumab has demonstrated preclinical synergy in small cell/neuroendocrine cancer cell lines and clinical tolerability is noted A multicenter phase II trial of the combination in NEPC was conducted.
Methods
Eligible patients had histologically proven prostate cancer with radiologic evidence of metastases and either: A) Small-cell or NEPC B) positive staining for chromogranin and synaptophysin C) visceral metastases and a PSA< 5 ng/dL.D) Serum chromogranin A level = 5× upper limit of normal (ULN) and/or serum neuron specific enolase (NSE) = 2× ULN. E) RB1 deletions or mutations F) Trans-differentiated or poorly-differentiated carcinoma. 2 prior chemotherapy regimens were allowed. Performance status of 0-1 and normal marrow, renal and liver function were required. Primary endpoint was 6- month radiologic progression-free survival (rPFS). Stud therapy was Lenvatinib 20 mg orally daily and intravenous pembrolizumab 200 mg every 21 days. Sample size was 27 for first stage and if 3 patients were progression free at 6 months then total accrual was 40 evaluable patients.
Results
33 patients enrolled; median age was 71 years (range- 37-83 years), 3 (10%) black patients and 3 (10%) of Hispanic ethnicity. 13/22 (59%) had Gleason ≥ 8, 31 (94%) patients had small cell/NEPC, 1 patient qualified based on serum NE markers, 1 had transdifferentiated histology. RB loss was noted in 3 of 11 patients. 12/31 (39%) patients had liver metastases and 30 (91%) had measurable disease. 31 (94%) patients received prior chemotherapy and 23 (70%) received prior platinum. No treatment related deaths were noted. Grade 4 toxicities of lipase elevation and urinary obstruction were noted in 1 patient each. Grade 3 toxicities of hypertension, diarrhea, fatigue and proteinuria occurred in 6, 2, 5 and 3 patients respectively. 21 pts are response evaluable to date. 3 (14%) had partial response. 7 (33%) had stable disease. Five patients remain progression free at 6 months. The primary endpoint of first stage was met. Accrual to second stage is ongoing. PFS and OS will be reported.
Conclusions
The combination of lenvatinib and pembrolizumab demonstrated tolerability and promising efficacy in a pretreated patient population with NEPC.
Clinical trial identification
NCT04848337.
Editorial acknowledgement
Legal entity responsible for the study
Hoosier Cancer Research Network.
Funding
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA provided drug and financial support.
Disclosure
U.N. Vaishampayan: Financial Interests, Personal, Advisory Board, consultant: BMS; Financial Interests, Personal, Advisory Board: Bayer, Gilead, Pfizer, Merck, Exelixis, Novartis; Financial Interests, Institutional, Research Grant, Investigator initiated trial supported by Merck: Merck; Non-Financial Interests, Member of Board of Directors: Michigan Society of Hematology/Oncology. D. Kilari: Financial Interests, Personal, Invited Speaker: Janssen, Pfizer, Aveo oncology, Seagen, MJH - life sciences, Binayatra foundation; Financial Interests, Personal, Advisory Board: Exelixis, Eisai; Financial Interests, Institutional, Coordinating PI: Exelixis, Genentech. T.B. Dorff: Financial Interests, Personal, Advisory Board: AstraZeneca, Janssen, Sanofi, Bayer. A.O. Sokolova: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Invited Speaker: Lantheus; Financial Interests, Personal and Institutional, Research Grant: AstraZeneca. Z. Reichert: Financial Interests, Personal, Advisory Board: Huff Powell Bailey, AstraZeneca; Financial Interests, Institutional, Coordinating PI: AstraZeneca, Celgene. J. Alumkal: Financial Interests, Personal, Advisory Board: Fibrogen; Financial Interests, Institutional, Funding: Pfizer, Beactica, Zenith; Financial Interests, Personal and Institutional, Advisory Role, Research award: Astellas; Financial Interests, Personal, Advisory Role: Bristol-Myers-Squibb. All other authors have declared no conflicts of interest.
Resources from the same session
1199P - Developing and systematically validating homologous recombination repair gene detection method based on next-generation sequencing
Presenter: Yi Sun
Session: Poster session 10
1200P - Investigation of multiphoton microscopy as an innovative tool for intraoperative section-free histologic investigations in just a few minutes
Presenter: Martí Homs Soler
Session: Poster session 10
1201P - Novel deep learning model and validation of whole slide images in lung cancer diagnosis
Presenter: Alhassan Ahmed
Session: Poster session 10
Resources:
Abstract
1202P - A deep learning approach using routine pathology images to guide precision medicine in metastatic CRC
Presenter: Chaitanya Parmar
Session: Poster session 10
1203P - Analytical evaluation of whole genome sequencing for acute myeloid leukemia
Presenter: Guidantonio Malagoli Tagliazucchi
Session: Poster session 10
1204P - Real-world utility of whole genome sequencing for patients with cancer: Evaluation of a regional implementation of the 100,000 genomes project
Presenter: Helen Robbins
Session: Poster session 10
1205P - A retrospective machine learning-based analysis of nationwide cancer CGP data across cancer types to identify features associated with recommendation of mutation-based therapy
Presenter: Hiroaki Ikushima
Session: Poster session 10
1478P - Dual single-nucleotide polymorphism biomarker combination to select opioid for cancer pain management
Presenter: Yoshihiko Fujita
Session: Poster session 10
1479P - Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational study
Presenter: Pablo Gallardo Melo
Session: Poster session 10
1480P - Long term therapy with denosumab and zoledronic acid: A comparative real-world retrospective observational study on skeletal-related events and pain in patients with metastatic breast cancer
Presenter: Giacomo Massa
Session: Poster session 10